Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 05, 2015 6:44 AM ET

Pharmaceuticals

Company Overview of AstraZeneca AB

Company Overview

AstraZeneca AB offers research, development, manufacture, and marketing of pharmaceutical products for gastrointestinal, cardiovascular, respiratory, and pain control.. The company was formerly known as Astra AB and changed its name to AstraZeneca AB in April 1999. The company was founded in 1913 and is based in Sodertalje, Sweden. AstraZeneca AB operates as a subsidiary of AstraZeneca PLC.

Karlebyhus

Astraallén

Sodertalje,  151 85

Sweden

Founded in 1913

24,958 Employees

Phone:

46 8 55 32 60 00

Fax:

46 8 55 32 90 00

Key Executives for AstraZeneca AB

President
Head of Production
Other Professional
Compensation as of Fiscal Year 2015.

AstraZeneca AB Key Developments

AstraZeneca AB (publ) and Hutchison MediPharma Limited Announce Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer

AstraZeneca AB (publ) (AstraZeneca) and Hutchison MediPharma Limited's (HMP) collaboration partner, presented preliminary data from the ongoing Phase Ib clinical trial of HMP's c-Met inhibitor savolitinib (AZD6094) combined with AstraZeneca's drug candidate AZD9291 in non-small cell lung cancer ("NSCLC"). AZD9291 is AstraZeneca's investigational inhibitor of the epidermal growth factor receptor (EGFR). Preliminary data on the activity of AZD9291 in patients with EGFR mutation positive NSCLC who had failed currently-approved EGFR tyrosine kinase inhibitors was presented at the American Society of Clinical Oncology (ASCO) meeting in June 2014. In mid-2014 AstraZeneca commenced the TATTON study, a multi-arm Phase Ib study of AZD9291 in combination with either savolitinib (AZD6094) (c-MET inhibitor), MEDI4736 (anti-PD-L1 mAb) or selumetinib (MEK1/2 inhibitor) in EGFR mutation positive NSCLC. For those patients who received AZD9291 and savolitinib, the primary objective of the TATTON study was to establish a safe and effective combination dose. All patients were screened for their T790M status (+/-) as well as some, if sufficient tissue samples were available, for their c-Met (+/-) status. A total of 12 patients were dosed with either 600mg or 800mg daily doses of savolitinib (AZD6094) in combination with 80mg (once daily) AZD9291. In terms of the primary aims of the study, the 600mg combination dose was well tolerated with toxicity profiles that allow for combination at doses previously demonstrated to be biologically active. Of the 11 evaluable patients in the study, 6 partial responses (confirmed and unconfirmed) have been observed to date. Responses to date include 4 of 7 patients with confirmed T790M negative status.

AstraZeneca Plans To Invest In Biotech Drug Factory In Sodertalje

AstraZeneca AB is investing $285 million to expand biotech drug manufacturing in Sweden as the company bets on the future of high-tech medicine for future growth. The new facility for biological medicines in Sodertalje will supply medicines for clinical trial programs from the end of 2018 and will deliver finished products for commercial use once fully operational by 2019. The planned investment will, subject to relevant approvals by the local authorities, create between 150 and 250 highly skilled new roles at AstraZeneca by 2019, AstraZeneca said in a statement.

AstraZeneca AB Presents at Bio-Trinity, May-13-2015 10:10 AM

AstraZeneca AB Presents at Bio-Trinity, May-13-2015 10:10 AM. Venue: Novotel London West, 1 Shortlands, London W6 8DR, United Kingdom. Speakers: Christoph Pittius, VP, Head of Transactions, Business Development.

Similar Private Companies By Industry

Company Name Region
Swedish Biotech Center Europe
Miwana AB Europe
CMC Contrast AB Europe
Baxter Medical AB Europe
Vitalas AB Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AstraZeneca AB, please visit www.astrazeneca.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.